Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jul 31, 2021

Filed with the SEC on Sep 14, 2021 and accepted by EDGAR at Sep 14, 2021, 08:01 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-07-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-05-01 to 2021-07-31$0us-gaap:Revenues
Research and development3 months2021-05-01 to 2021-07-31$143.6kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-05-01 to 2021-07-31−$1.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2021-05-01 to 2021-07-31$467us-gaap:InterestExpense
Net income3 months2021-05-01 to 2021-07-31−$1.0mus-gaap:NetIncomeLoss
Diluted shares (weighted)3 months2021-05-01 to 2021-07-311,591,306 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2021-05-01 to 2021-07-31−$1.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2021-07-31$959.3kus-gaap:Cash
Current assetsAt period end2021-07-31$1.5mus-gaap:AssetsCurrent
Total assetsAt period end2021-07-31$6.6mus-gaap:Assets
Current liabilitiesAt period end2021-07-31$925.0kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-07-31$925.0kus-gaap:Liabilities
Shareholders' equityAt period end2021-07-31$5.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-21-004264. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.